Stem cell-derived pancreatic endocrine cell clusters
Type 1 Diabetes
Pre-clinicalActive
Key Facts
About Seraxis
Seraxis is a private, clinical-stage biotech focused on a stem cell-derived islet replacement therapy for Type 1 Diabetes. Its core technology is based on a proprietary, engineered stem cell line designed to produce pure, potent, and immunologically compatible pancreatic endocrine cells. The company is advancing its lead program toward clinical trials and is actively seeking strategic partnerships to accelerate development and broaden the application of its platform.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |
| Type I Diabetes | Genclis | Discovery |
| Inreda AP® | Inreda Diabetic | Commercial |
| iTOL-101 | iTolerance | Preclinical |